Quack’s ‘Treatment’ Paralyses 68-Year-Old Woman In Telangana

HYDERABAD:  A 68-year-old woman from Tandur was left bedridden, with total loss of sensation in one leg, after receiving ‘treatment’ from a quack two months ago. The case came to light on Friday after the woman’s family got into an altercation with the accused.

On learning of the malpractice, Telangana State Medical Council (TGMC) is taking it up as a suo moto case to file an FIR against the unqualified practitioner, Mukith.Mukith had been under TGMC’s radar and escaped a raid at his clinic a fortnight ago. He managed to flee from his clinic in Daulatabad in Vikarabad, where he had administered three steroid injections to the patient, Lakshmibai, who had sought treatment from him for knee pain.

‘Quack gave woman 3 steroid injections’

The injections Mukith administered led to sepsis of the knee joint, a swollen leg and fever.

Lakshmibai was rushed to another doctor who performed surgery to remove the infected tissue.

Orthopaedic surgeon Dr Santosh Kumar, who is treating Lakshmibai, said: “She was given three steroid injections in the knee joints. These injections are prescribed only for certain conditions… When she came to me, her entire knee joint was damaged due to sepsis. The family also lost all their money in getting treatment from the quack. Although her leg was saved, it is completely unstable and has no sensation…”

Mukith was among the seven unqualified practitioners raided a fortnight ago by TGMC officials. Six FIRs were lodged after the raids in Parigi, Moinabad, and Daulatabad areas. “We had prescriptions of Mukith, but when the raid started in Daulatabad, he got the information through their network. He shut down the clinic and fled,” said TGMC chief Dr G Srinivas.

Related Posts

  • Pharma
  • June 24, 2025
  • 91 views
Glenmark Pharma launches TEVIMBRA in India

Glenmark Pharmaceuticals announced that it had launched TEVIMBRA (tislelizumab) in India after receiving approval from the Central Drugs Standard Control Organization (CDSCO). The drug is a specially designed anti-PD-1 monoclonal…

  • Pharma
  • June 24, 2025
  • 93 views
India’s herbal and ayurvedic OTC market set to outpace global growth

New Delhi: India’s herbal and ayurvedic OTC (over the counter) market is expected to grow at a CAGR of 6.5 per cent, from $69 million in 2025 to $118 million…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Glenmark Pharma launches TEVIMBRA in India

Glenmark Pharma launches TEVIMBRA in India

India’s herbal and ayurvedic OTC market set to outpace global growth

India’s herbal and ayurvedic OTC market set to outpace global growth

Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug

Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug